ArticleCancer medicine2020
Health-related quality of life of patients with multiple myeloma: A real-world study in China.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.Advances in therapy · 2022Pooled it
- Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.Frontiers in oncology · 2021Pooled it
- Nutritional vulnerability, food insecurity, and unmet supportive care needs in multiple myeloma: a cross-sectional study from China.Frontiers in nutrition · 2026Article
- Quality of Life Among Polish Patients with Multiple Myeloma: A Cross-Sectional Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Minimal clinically important difference of EQ-5D-5L, SF-6Dv2, and QLU-C10D in hematologic malignancy patients in China.Health and quality of life outcomes · 2025Article
- Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study.Health and quality of life outcomes · 2025Article
- [Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Review
- Myélome multiple et approche palliative des soins : étude théorique ancrée dans la pratique.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2024Article
- Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma.Revista brasileira de enfermagem · 2024Article
- The experiences of living with multiple myeloma and a palliative approach to care: A grounded theory study.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2024Article
- Assessment tools for patient-reported outcomes in multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Analysis of Hazard Factors Affecting the Quality of Life for Lung Cancer Patients after Chemotherapy.Journal of healthcare engineering · 2022Article
- Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma.Frontiers in oncology · 2021Article
- Health-related quality of life of patients with multiple myeloma: A real-world study in China.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the health-related quality of life (HRQOL) of Chinese patients with different stages of multiple myeloma (MM) who received various treatments and identify the factors associated with a lower quality of life in China.
methodsA cross-sectional, anonymous questionnaire was distributed to adults with MM. The measures of quality of life included the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30, QLQ-myeloma-specific module 20 (MY20), and EuroQoL EQ-5D. The data, including patient factors, difficulties experienced during the diagnosis and treatment processes, psychosocial factors and disease- or treatment-related effects, were collected.
resultsFour hundred and thirty patients with MM were recruited from all 27 provinces of China, and their average age was 55.7 years. Many variables were significantly associated with the HRQOL of the patients with MM. In the multivariate analyses, performance status, psychosocial factors, disease phase, and an early diagnosis were significantly associated with the HRQOL. In the subgroup analysis, the HRQOL of the patients who underwent autologous stem cell transplantation (ASCT) was significantly higher than that of the non-ASCT patients. Treatment-related toxicities had a significant impact on the quality of life of the patients with MM, and 91.5% of the patients intended to stop the maintenance treatment.
conclusionsThe quality of life of patients with MM in China is affected by patient factors, difficulties experienced during the diagnosis and treatment processes, psychosocial factors, and disease- or treatment-related effects. Efforts should be exerted to improve the overall quality of life of these patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.